TPU-002 is being developed for the treatment of Parkinson’s disease. This product uses Teikoku’s unique transdermal drug delivery system and contains the same active drug component in AZILECT®, the only currently marketed form of rasagiline. Teikoku believes that our TPU-002 offers potential advantages over AZILECT® oral and could seize a meaningful share of this rapidly growing market.
About the Parkinson’s Disease Market
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. There are between 1 and 1.5 million Americans living with Parkinson’s disease. Worldwide patient population is estimated to 4 million and projected to grow to over 9 million cases. The main symptoms (stiffness, tremors, and slowed movements and gait) are caused by a loss of dopamine production by the neurons that are involved in controlling movement and coordination. Overall, world revenue for drugs treating PD will reach $3,426M in 2016. There are 8 major anti-Parkinson drugs in U.S. market with MIRAPEX®, Carbidopa/levodopa, and REQUIP®. AZILECT® had 2013 sales of $240M in the US and $248M for Europe and Asia market, and is still enjoying sales growth of 19.4% growth in the US.
Besides the foremost need to develop a therapy to slow Parkinson’s disease progression, several other important needs exist:
- Alternative delivery systems to counter difficulty swallowing
- New less side-effect laden drugs for the delay of onset of dementia
- Cure that repairs and/or reverses the damage
- Simplification of complex medical regimens